Genenta Science(US:GNTA) Globenewswire·2026-01-27 08:00Core Viewpoint - Genenta Science S.p.A is transforming into Saentra Forge S.p.A, focusing on acquiring privately held businesses in national-security regulated sectors under Italian Golden Power legislation, targeting companies with up to €5 million in EBITDA [1][10] Group 1: Strategic Transformation - The company aims to become a next-generation strategic industrial consolidator, pursuing a value-creation strategy by acquiring targets at private-market valuations and integrating them under Saentra Forge [2] - The first acquisition target is ATC, a defense-sector company specializing in high-precision manufacturing of tactical rifles and special-forces weapon systems [3] Group 2: Financial Projections and Funding - Genenta plans to fund ATC with a total of €5.1 million through performance-driven tranches, aiming for a controlling position upon achieving defined performance milestones [3] - ATC projects revenues of approximately €4.0 million in 2026, increasing to around €9.0 million by 2027, with an expected EBITDA of more than €2.0 million in 2026, potentially doubling in 2027 [3] Group 3: Governance and Strategic Partnerships - The Praexidia Foundation has joined as a strategic long-term shareholder, enhancing the company's governance framework and supporting regulatory coherence [4][5] - A shareholders' agreement has been established to ensure consultation rights on significant corporate transactions and a renewable five-year lock-up, reinforcing long-term alignment and effective control [5] Group 4: Biotech and Cash Position - The company has reached key clinical milestones in its cell therapy platform, engaging DC Advisory as its exclusive financial advisor for partnership initiatives [6] - Expected cash, cash equivalents, and marketable securities at December 31, 2025, are approximately $33 million, up from $17.7 million at June 30, 2025, primarily due to a registered direct offering [9]